Systemic, i.v. administration of anti-CTLA-4 can also result in activated naïve-T cells in non-tumor draining LNs where non-tumor, self Ags rather than tumor Ags are presented (Figure 1, insert B), and presumably lead to irAEs. The gene discussed is CTLA4; the disease is neoplasm.